Paul L. Hermonat

Paul L. Hermonat

Auto-generated profile, based on publicly available information

Paul L. Hermonat

Central Arkansas Veterans Healthcare System, 111J, 4300 West 7th Street, Little Rock,AR 72205, USA; Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, 4301 West Markham St., Little Rock, AR 72205, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMaohua Cao
Maohua Cao
HYHong You
Hong You
PHPaul L. Hermonat
Paul L. Hermonat
Adeno-associated virus (AAV) (type 2) is a popular human gene therapy vector with a long active transgene expression period and no reported vector-induced adverse reactions. Yet the basic molecular biology of this virus has not been fully addressed. One potential gene at the far 3′ end of the AAV2 genome, previously referred to as X (nt 3929 to 4393), overlapping the 3′ end of the cap gene, has never been characterized, although we did previously identify a promoter just up-stream (p81). Computer analysis suggested that X was involved in replication and transcription. The X protein was identified during active AAV2 replication using a polyclonal antibody against a peptide starting at amino acid 98. Reagents for the study of X included an AAV2 deletion mutant (dl78-91), a triple nucleotide substitution mutant that destroys all three 5′ AUG-initiation products of X, with no effect on the cap coding sequence, and X-positive-293 cell lines. Here, we found that X up-regulated AAV2 DNA replication in differentiating keratinocytes (without helper virus, autonomous replication) and in various forms of 293 cell-based assays with help from wild type adenovirus type 5 (wt Ad5) or Ad5 helper plasmid (pHelper). The strongest contribution by X was seen in increasing wt AAV2 DNA replication in keratinocytes and dl78-91 in Ad5-infected X-positive-293 cell lines (both having multi-fold effects). Mutating the X gene in pAAV-RC (pAAV-RC-3Xneg) yielded approximately a ∼33% reduction in recombinant AAV vector DNA replication and virion production, but a larger effect was seen when using this same X-knockout AAV helper plasmid in X-positive-293 cell lines versus normal 293 cells (again, multi-fold). Taken together these data strongly suggest that AAV2 X encodes a protein involved in the AAV life cycle, particularly in increasing AAV2 DNA replication, and suggests that further studies are warranted.

26 June 2002
Verified
Journal Article
Closed access
YLY Liu
Y Liu
VKV S Klimberg
V S Klimberg
NAN R Andrews
N R Andrews
CHC R Hicks
C R Hicks
HPH Peng
H Peng
PHP L Hermonat
P L Hermonat

1 August 2015 in Virology
Verified
Journal Article
Closed access
MCM. Cao
M. Cao
MCM. Chiriva-Internati
M. Chiriva-Internati
PHP.L. Hermonat
P.L. Hermonat

6 April 2004 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
BFB. Franceschini
B. Franceschini
Fabio GrizziFabio Grizzi
Fabio Grizzi
PCPiergiuseppe Colombo
Piergiuseppe Colombo
GSGiuseppe Soda
Giuseppe Soda
KBK. Bumm
K. Bumm
MCMaurizio Chiriva-Internati
Maurizio Chiriva-Internati

20 September 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HZHongqing Zhu
Hongqing Zhu
MCMaohua Cao
Maohua Cao
JFJose A Figueroa
Jose A Figueroa
ECEverado Cobos
Everado Cobos
BUBarry F Uretsky
Barry F Uretsky
PHPaul L Hermonat
Paul L Hermonat
Inflammation is a key etiologic component in atherogenesis and transforming growth factor beta 1 (TGFβ1) is a well known anti-inflammatory cytokine which potentially might be used to limit it. Yet TGFβ1 is pleiomorphic, causing fibrosis, cell taxis, and under certain circumstances, can even worsen inflammation. SMAD3 is an important member of TGFβ1’s signal transduction pathway, but is a fully intracellular protein. With the hope of attenuating TGFβ1’s adverse systemic effects (eg. fibrosis) and accentuating its anti-inflammatory activity, we proposed the use of human (h)SMAD3 as an intracellular substitute for TGFβ1. To test this hypothesis adeno-associated virus type 2/8 (AAV)/hSMAD3 or AAV/Neo (control) was tail vein injected into the low density lipoprotein receptor knockout (LDLR-KO) mice, then placed on a high-cholesterol diet (HCD). The hSMAD3 delivery was associated with significantly lower atherogenesis as measured by larger aortic cross sectional area, thinner aortic wall thickness, and lower aortic systolic blood velocity compared with Neo gene-treated controls. HSMAD3 delivery also resulted in fewer aortic macrophages by immunohistochemistry for CD68 and ITGAM, and quantitative reverse transcriptase polymerase chain reaction analysis of EMR and ITGAM. Overall, aortic cytokine expression showed an enhancement of Th2 response (higher IL-4 and IL-10); while Th1 response (IL-12) was lower with hSMAD3 delivery. While TGFβ1 is often associated with increased fibrosis, AAV/hSMAD3 delivery exhibited no increase of collagen 1A2 or significantly lower 2A1 expression in the aorta compared with Neo-delivery. Connective tissue growth factor (CTGF), a mediator of TGFβ1/SMAD3-induced fibrosis, was unchanged in hSMAD3-delivered aortas. In the liver, all three of these genes were down-regulated by hSMAD3 gene delivery. These data strongly suggest that AAV/hSMAD3 delivery gave anti-atherosclerosis therapeutic effect without the expected undesirable effect of TGFβ1-associated fibrosis.

30 September 2006 in Fertility and Sterility
Verified
Journal Article
Closed access
MMM. Mahadevan
M. Mahadevan
YLY. Liu
Y. Liu
CYC. You
C. You
RLR. Luo
R. Luo
HYH. You
H. You
PHP.L. Hermonat
P.L. Hermonat